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Cancer is a major risk disease affecting human survival. The pharmaceutical companies are continuing searching for new 
drug candidates with promising anticancer activities, and reduced side effects. The current work aimed at synthesized a new 
tripeptide with potential pharmacological properties. L-Valine methyl ester was used to prepare cyclo (Nα-dinicotinoyl)- 
bis-[(L-valinyl)-L-lysine methyl ester. The new compound revealed promising in vitro cytotoxic activities against different 
neuroblastoma, cervical carcinoma, fibrosarcoma as well as hepatocellular carcinomas. Furthermore, we also found that the 
obtained IC50 of the compound decreased by about 50% during its in vivo anti-prostate cancer evaluation. Furthermore, the 
mechanism of action studies proposes that the new prepared derivative affects cancer cells trough the inhibition of  
VEGFR-2 kinase enzyme. 
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Introduction 
Cancer is one of the most powerful mankind 
threatening disease, due to its high mortality rate as 
well as difficult treating procedures and harmful  
side effects1,2. The pharmaceutical industry 
encourages continuous discovery of novel  
organic derivatives possessing potential anticancer 
activities, with the aim to combat cancer3. 
Heterocyclic ester derivatives have been identified as 
biologically significant components of medicinal 
chemistry1, such as: antiviral, anti-inflammatory, 
antioxidant, anti-HIV, and anticancer agents4,5. On the 
other hand, peptide candidates have been recognized 
as interesting exhibiting a broad spectrum of 
biological and pharmacological activities6-8. In view 
of these observations and in continuation of our 
previous work9-17 in heterocyclic and peptide 
chemistry, herein we reported thein vitro and in vivo 
cytotoxic activities and kinase inhibition of newly 
synthesized cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-
L-lysine methyl ester] derivative. 
Materials and Methods 
Synthesis of cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine 
methyl ester] (3) 
Compound 3 was synthesized by reaction of 3, 
5-pyridine dicarbonyl dichloride (1) with L-valine 
methyl ester followed by hydrolysis to corresponding 
diacid 2, which wascyclized with L-lysine methyl ester 
by using Mixed anhydride method according to 
reported procedure. The tested compound 3 was 
previously characterized by physical and spectroscopic 
data which were reported by Amr et al.15. 
 
Biological Activities  
In vitro cytotoxicity screening 
Various cancer cell lines (Table 1) were evaluated. 
Cells were cultivated and propagated using standard 
medium and conditions using standard cell culture 
protocols developed by our group18-21. After inoculation, 
plates were incubated at standard conditions for 24 h. 
After that, two plates/cell line, were fixed using TCA. 
Control references were dissolved in DMSO at 
comparable concentration doses. Plates were then 
processed as previously mentioned in the protocols. 
Absorbance was read at 515 nm and the IC50values were 
calculated from the regression analysis of the data.  
——————— 
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In vivo cytotoxic activity  
During this section, we used male Wistar rats 
obtained from the Animal House Colony, Research 
Institute of Ophthalmology, Giza, Egypt. Experiments 
were performed according to standard protocol22. 
 
VEGFR-2 kinase activity assays by ELISA   
This work was carried out according to standard 
protocol23 using Sorafenibas a positive control. The 
absorbance was measured at 492 nmand IC50  
values were calculated from the inhibition rate 
percentage equation23.  
 
Results and Discussion 
Chemistry 
Macrocyclic tripeptidopyridine candidate 3 was 
synthesized (Figure 1) and characterized by physical, 
chemical and spectroscopic evidences in advance 
according to our previous work19. In the current study, 
we report the evaluation and activities of these 
compounds as possible anticancer agents. 
 
Biological Screening 
Screening of in vitro cytotoxic activities 
The cytotoxicity of the tested compounds was 
determined on seventeen different human cancer cell 
lines (Figure 2). Screening results showed that the 
prepared compound exhibited variable potentials 
against difference tested cancer cells. This is in 
accordance with our previous results obtained 
showing that different cells respond differently 
towards investigated drugs15,17-19. This is due to 
differences between different cell types in terms of 
membrane structure and cell organization. 
Furthermore, comparing obtained results (in terms of 
IC50 values) with those recorded for standard 
pharmaceutical drugs showed that comparable IC50 
Table 1 — Different cell lines and reference drugs used throughout the work 
Cell line Type Cell line Type Cell line Type 
KB Cervical carcinoma U937 Leukemia HeLa Cervical carcinoma 
SKOV-3 Ovarian carcinoma K562 Leukemia MCF-7 Breast carcinoma 
SF-268 CNS cancer G361 Melanoma HT1080 Fibrosarcoma 
NCI H460 Non-small lung cancer SK-MEL-28 Melanoma HepG2 Liver carcinoma 
RKOP27 Colon adenocarcinoma GOTO Neuroblastoma PC-3 Prostate carcinoma 
HL60 Leukemia NB-1 Neuroblastoma   
Reference drugs  
Sorafenib Fluorouracil Doxorubicin Cytarabine 
Gemcitabine Capecitabine Aldesleukin Paclitaxel 
Epirubicin Imatinib Bicalutamide Flutamide 
 
 
 
Fig. 1 — Synthetic route for cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine methyl ester] 3. 
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values were obtained for colon adenocarcinoma  
(4.56 and 4.33 nM for compound3 and Capecitabine, 
respectively), for the neuroblastoma NB-1 (6.0 and 5.15 
nM for compound 3 and Doxorubicin, respectively), as 
well as the prostate cancer PC-3 cell line (9.76 and 8.22 nM 
for compound 3 and Bicalutamide, respectively). On the 
other hand, our prepared compound showed higher 
potential cytotoxic activities, where it showed almost  
2-folds activity against the neuroblastoma GOTO cells 
(IC50: 2.34 and 4.37 nM for compound 3 and 
Doxorubicin, respectively), 2.6-folds activity against 
HeLa cells (IC50: 4.55 and 11.8nM for compound 3  
and Paclitaxel, respectively), 21-folds activity against 
the fibrosarcoma HT1080 (IC50: 6.2 and 130.24 nM for 
compound 3 and Imatinib, respectively) and 5.5-folds 
activity against the HepG2 cells (IC50: 6.2 and 34.4 nM 
for compound 3 and Gemcitabine, respectively). 
 
In vivo activity 
In vivo anti-prostate data showed potential anti-
prostate activity for compound 3 in experimental 
animal model. The obtained significant ED50 value 
observed for compound (5) (5.26 ± 0.034 μM) was 
2.2-folds higher than that obtained for the Flutamide 
reference drug (11.6 ± 0.09 μM). 
 
VEGFR-2 inhibition 
Anti-VEGFR-2 results revealed that the 
synthesized compound (3) exhibited potent VEGFR-2 
inhibitory activity, where the obtained IC50 value 
(1.91nM) showed about 5% activity higher than the 
Sorafenib reference drug (2 nM).  
 
Conclusion 
Within the framework of the current investigation, 
we were able to synthesize a new cyclo  
(Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine methyl  
ester from the reaction of dicarbonyl dichloride and  
L-valine methyl ester. The new derivative exhibited 
potent in vitro cytotoxic activities against 
neuroblastoma, cervical carcinoma, fibrosarcoma as well 
as hepatocellular carcinomas in comparison to standard 
 
 
Fig. 2 — Cytotoxic activities of Cpd. 3 against different evaluated cell lines 
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reference drugs. Furthermore, the new derivative 
showed 2.2-folds increased in vivo anti-prostate cancer 
activity, compared to control drug. These results support 
the potential use of the new derived tripeptide as a 
promising pharmaceutical molecule with potential in 
vitro and in vivo anticancer properties. 
 
Abbreviations 
IC50 Half maximal inhibitory concentration  
ED50 Median effective dose 
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